指南与共识消化系统肿瘤

共识分子亚型作为RAS野生型转移性结直肠癌一线治疗生物标志物的个体患者数据荟萃分析

Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
指南 / 共识 · J Clin Oncol · 2025-11-18

结果显示CMS2和CMS4较CMS1有更长的PFS和OS,且CMS4肿瘤中抗EGFR较抗VEGF抗体显著改善PFS和OS。结论提示CMS4可能是RAS(及BRAF)野生型mCRC抗EGFR治疗疗效的附加生物标志物。

要点

  • CMS2和CMS4较CMS1有显著更长的PFS和OS。
  • CMS4肿瘤中抗EGFR较抗VEGF显著改善PFS和OS。
  • CMS4可能是RAS/BRAF野生型mCRC抗EGFR疗效的附加生物标志物。

核心结论

  • CMS4可能是RAS(及BRAF)野生型转移性结直肠癌抗EGFR治疗疗效的附加生物标志物。

研究设计与样本

  • 采用一步法IPD荟萃分析,ORR用广义估计方程模型,PFS/OS用Cox模型,并考虑研究内患者聚类。

主要发现

  • CMS分布:CMS1 77例(9.7%)、CMS2 345例(43.7%)、CMS3 74例(9.4%)、CMS4 294例(37.2%)。

关键数值与推荐

  • 抗EGFR对比抗VEGF在CMS4肿瘤中改善PFS和OS,RAS/BRAF野生型及MSS亚组一致。
  • 研究间异质性可忽略(方差<1×10^-6)。

临床怎么用

  • 对RAS野生型mCRC患者,可考虑检测CMS分型,CMS4提示抗EGFR抗体可能优于抗VEGF。
  • CMS4且RAS/BRAF野生型或MSS状态时,抗EGFR治疗获益一致,支持该生物标志物的临床参考价值。

局限性

  • CMS3样本量较小(74例),相关比较未详细报告。
  • ORR比较中CMS2和CMS4较CMS1的差异未达统计学显著性。
  • 研究基于5项试验的回顾性IPD,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Consensus molecular subtypes (CMSs) of metastatic colorectal cancer (mCRC) are debatable biomarkers. An individual patient data (IPD) meta-analysis was performed to test for impact on objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS), and treatment interaction. METHODS: IPD (RAS wild-type [WT] tumors treated per protocol [fluorouracil/capecitabine, irinotecan/oxaliplatin, anti-vascular endothelial growth factor {VEGF}/anti-epidermal growth factor receptor {EGFR} antibodies] and with evaluable CMSs) were collected from five trials identified in PubMed, Embase, Medline, Cochrane Library, and proceedings of ASCO/European Society for Medical Oncology: FIRE1 (no identifier), FIRE3 (ClinicalTrials.gov identifier: NCT00433927), XELAVIRI (ClinicalTrials.gov identifier: NCT01249638), PanaMa (ClinicalTrials.gov identifier: NCT01991873), and TRIBE2 (ClinicalTrials.gov identifier: NCT02339116). The one-step IPD meta-analysis approach assessed data taking the clustering of patients in the studies into account (ORR: generalized estimating equations models; PFS/OS: Cox models). RESULTS: Seven hundred ninety patients were included: CMS1, n = 77 (9.7%); CMS2, n = 345 (43.7%); CMS3, n = 74 (9.4%); and CMS4, n = 294 (37.2%). Between-study heterogeneity was negligible (variance < 1 × 10-6). Compared with CMS1, CMS2 and CMS4 tumors had numerically higher odds ratios (OR) for ORR (CMS2: OR, 1.668 [95% CI, 0.982 to 2.836]; P = .059; CMS4: OR, 1.369 [95% CI, 0.874 to 2.146]; P = .170), and longer PFS (CMS2: hazard ratios [HR], 0.64 [95% CI, 0.48 to 0.85]; P = .002; CMS4: HR, 0.67 [95% CI, 0.50 to 0.91]; P = .009) and OS (CMS2: HR, 0.59 [95% CI, 0.43 to 0.80]; P < .001; CMS4: HR, 0.67 [95% CI, 0.49 to 0.92]; P = .01). The use of anti-EGFR versus anti-VEGF antibodies meaningfully improved PFS (HR, 0.67 [95% CI, 0.46 to 0.97]; P = .03) and OS (HR, 0.49 [95% CI, 0.33 to 0.72]; P < .001) in CMS4 tumors and was consistently observed for CMS4 RAS/BRAF WT (HR, 0.55 [95% CI, 0.37 to 0.83]; P = .004) or microsatellite stable status (HR, 0.52 [95% CI, 0.32 to 0.86]; P = .01). The interaction test of antibody treatment with CMSs was significant for PFS (P < .001) and OS (P < .001) in all patients and for OS in patients with RAS/BRAF WT tumors (P = .02). CONCLUSION: CMS4 might be an additional biomarker of anti-EGFR treatment efficacy in RAS (and BRAF) WT mCRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stahler A, Modest DP, Stintzing S, et al. Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. J Clin Oncol. 2025. PMID: 41252656. doi:10.1200/JCO-25-00596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。